Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

Autor: Shafak Aluwini, Floris Pos, Erik Schimmel, Emile van Lin, Stijn Krol, Peter Paul van der Toorn, Hanja de Jager, Maarten Dirkx, Wendimagegn Ghidey Alemayehu, Ben Heijmen, Luca Incrocci

Publikováno v: Lancet Oncology, 16, 3, pp. 274-83
Lancet Oncology, 16(3), 274-283. Lancet Publishing Group
The Lancet Oncology, 16(3), 274-283
Lancet Oncology, 16, 274-83

Item does not contain fulltext BACKGROUND: In 2007, we began the randomised phase 3 multicentre HYPRO trial to investigate the effect of hypofractionated radiotherapy compared with conventionally fractionated radiotherapy on relapse-free survival in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9045f8454486b5cdbf48d258b84aff2
https://doi.org/10.1016/s1470-2045(14)70482-6

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

Autor: Floris J. Pos, Peter Paul van der Toorn, Maarten L.P. Dirkx, E. Schimmel, Shafak Aluwini, Luca Incrocci, Wendimagegn Ghidey Alemayehu, Emile van Lin, Ben J.M. Heijmen, Stijn Krol, Hanja de Jager

Publikováno v: Lancet Oncology, 17(4), 464-474. Lancet Publishing Group
The Lancet Oncology, 17(4), 464-474

Summary Background Several studies have reported a low α to β ratio for prostate cancer, suggesting that hypofractionation could enhance the biological tumour dose without increasing genitourinary and gastrointestinal toxicity. We tested this theor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a910d791b28e352f73e5db53310c66e
https://pure.eur.nl/en/publications/ebb7bf45-0e0d-4579-9edb-01c6df1bc5b4